Transcriptome-Based Six-Gene Fatty Acid Metabolism Signature for Prognosis and Predicted Immunotherapy Response in Lung Adenocarcinoma: Cross-Population Validation
Genes · 31.07.2026 · 17 (8) · 914
DOI: 10.3390/genes17080914 ↗Kurz gefasst
Fachartikel in der Zeitschrift Genes, online erschienen am 31.07.2026. Verfasst von Qiangping Ma und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Clinical Medicine of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou 730101, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Fatty Acids, Lung Neoplasms, Transcriptome. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Gansu University of Traditional Chinese Medicine, Open Project of the Key Laboratory of Dunhuang Medicine and Transformation, Ministry of Education.
Abstract (Originalsprache)
Objectives
Lung adenocarcinoma (LUAD) is molecularly heterogeneous, and the prognostic relevance of fatty acid metabolism (FAM) remains incompletely defined. We aimed to develop a concise FAM-associated prognostic signature and examine its associations with the immune microenvironment and candidate therapeutic vulnerabilities.
Methods
TCGA-LUAD transcriptomic and survival data were integrated with MSigDB FAM gene sets. Univariate Cox and elastic-net Cox regression were used to derive a risk score. The locked formula was evaluated in a Japanese cohort (GSE31210) and a U.S. cohort (GSE72094). Immune-infiltration algorithms as well as TIDE, GDSC2, and CPTAC data were used for exploratory immune, drug sensitivity, and protein-level analyses.
Results
The six-gene signature comprised CYP4B1, ACOXL, DPEP2, HPGDS, CA4, and ALOX15. High-risk patients had shorter overall survival in the TCGA and both external cohorts (GSE31210, log-rank p = 0.0039; GSE72094, p < 0.0001). The risk score remained independently prognostic after adjustment for age, sex, and clinical stage. High-risk tumours showed lower immune and stromal signals, greater immune exclusion, and a lower TIDE-predicted ICB response proportion. GDSC2 analyses and expression comparisons identified associations with predicted drug sensitivity and lipogenic target expression. Five detectable signature proteins were less abundant in tumours in CPTAC data.
Conclusions
This signature stratified patients by prognosis in two geographically distinct external cohorts and generated testable metabolic and immune hypotheses. Prospective validation, assay standardisation, and functional studies are required before clinical use.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Clinical Medicine of Traditional Chinese Medicine, Gansu University of Chinese Medicine, Lanzhou 730101, China.
- Key Laboratory of Dunhuang Medicine and Transformation, Ministry of Education, Lanzhou 730000, China.
- School of Basic Medical Sciences, Gansu University of Chinese Medicine, Lanzhou 730101, China.
Förderung
- National Natural Science Foundation of China
- Gansu University of Traditional Chinese Medicine
- Open Project of the Key Laboratory of Dunhuang Medicine and Transformation, Ministry of Education
- 2024 ‘Qihuang Talents’ Mentor Special Fund (Doctoral Supervisor Project) for the First-Level Discipline of Traditional Chinese Medicine
Zitieren
APA
Ma, Q., Liang, J., Li, J., & Li, J. (2026). Transcriptome-Based Six-Gene Fatty Acid Metabolism Signature for Prognosis and Predicted Immunotherapy Response in Lung Adenocarcinoma: Cross-Population Validation. Genes, 17(8), 914. https://doi.org/10.3390/genes17080914
Vancouver
Ma Q, Liang J, Li J, Li J. Transcriptome-Based Six-Gene Fatty Acid Metabolism Signature for Prognosis and Predicted Immunotherapy Response in Lung Adenocarcinoma: Cross-Population Validation. Genes. 2026;17(8):914. doi:10.3390/genes17080914
BibTeX
@article{Ma2026,
author = {Ma, Qiangping and Liang, Jianqing and Li, Jintian and Li, Juan},
title = {Transcriptome-Based Six-Gene Fatty Acid Metabolism Signature for Prognosis and Predicted Immunotherapy Response in Lung Adenocarcinoma: Cross-Population Validation},
journal = {Genes},
year = {2026},
volume = {17},
number = {8},
pages = {914},
doi = {10.3390/genes17080914}
}
EUVIMED